ORLANDO, FL -- April 22, 2022 -- InvestorsHub NewsWire -- via
Emerging
Markets -- Sometimes as we continue our coverage
of Mindset Pharma Inc. (Mindset) (CSE:
MSET) (FSE: 9DF) (OTCQB:
MSSTF) it feels as if we are covering TWO unique
stories.
And maybe we are.
As you may recall, Mindset is a drug discovery and development
company focused on creating next-generation psychedelic medicines
to treat neurological and psychiatric disorders. Most of what we
cover about Mindset are the Company's advancements in drug
development that assist them in their perpetual goal of helping
patients have better outcomes using psychedelics.
But perhaps the larger, parallel story is that this
psychedelics-as-medicine paradigms seems to be at a point that real
treatments are emerging and doctors and companies are learning from
these early treatments.
This article from
Harvard Health Publishing talks both about how far
psychedelics have come … and how far they might go.
And this article
from the venerable New York Times leads with the bold
headline, "The Psychedelic Revolution is Coming. Psychiatry
May Never Be the Same."
That's why the recent
news from psychedelic pioneers Mindset Pharma is
incredibly important. In the release, Mindset announces the filing
of a new provisional patent application that covers new chemical
entities (NCEs) that expand the Company's next-generation DMT and
5-MeO-DMT, or 'Family 4', platform, currently under
development.
This new patent application exemplifies the Mindset corporate
strategy to broaden the therapeutic psychedelic toolbox for
patients with mental health disorders who are waiting for
transformative medicines and covers novel chemical space while
maintaining the functionality of traditional psychedelics.
A quote from CEO James Lanthier explains the significance of the
filing:
"As we get more human clinical data from first generation
psychedelic drugs, we will unravel how different patients respond
to different psychedelic therapies. Our expectation is that
different patients will respond to different treatments and
paradigms. In an effort to build a toolbox that helps the most
patients, Mindset continues to build out its patent portfolio."
And that's the part we think is compelling, even resonant.
Mindset is growing in a growth industry, developing more options as
acceptance broadens and the earth moves under its proverbial feet.
Remember when Washington and Colorado were rebels, bold early
adopters that were the
first states to legalize recreational cannabis use? Now, we're
talking about the possible end to federal prohibition as a vast
amount of states allow recreational and medical use.
We may be at a similar precipice, a tipping point. Those
articles from The New York Times and Harvard are
from last year. Since that time Mindset has put more tools in the
tool box.
And let's not kid ourselves. Mindset is a public company and as
much as the narrative is and should be about the potentially
transformative effects of psychedelic treatments, the story may
someday be about a Company who has generated intellectual property
with potential revenue streams that could be valuable in a fully
exploited psychedelic health care market.
It wasn't that long ago that
Oregon was the first to legalize psychedelic mushrooms, a move
that if similar to the seminal decriminalization of cannabis in
Washington and Colorado a decade ago, could lead a very large
psychedelic treatment market sooner than later.
If that happens, Mindset is already well down the road of
putting tools in the toolbox.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated
by Emerging Markets Consulting (EMC), a syndicate of investor
relations consultants representing years of experience. Our network
consists of stockbrokers, investment bankers, fund managers, and
institutions that actively seek opportunities in the micro and
small-cap equity markets.
For more informative reports such as this, please sign up
at https://emergingmarketsconsulting.com/
Must Read OTC Markets/SEC policy on stock promotion and
investor protection
Section 17(b) of the Securities Act of 1933 requires that any
person that uses the mails to publish, give publicity to, or
circulate any publication or communication that describes a
security in return for consideration received or to be received
directly or indirectly from an issuer, underwriter, or dealer, must
fully disclose the type of consideration (i.e. cash, free trading
stock, restricted stock, stock options, stock warrants) and the
specific amount of the consideration. In connection therewith, EMC
has received the following compensation and/or has an agreement to
receive in the future certain compensation, as described below.
EMC has been paid $250,000 by Mindset Pharma, Inc. for various
marketing services including this report. EMC does not
independently verify any of the content linked-to from this
editorial. https://emergingmarketsconsulting.com/disclaimer/
Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave STE 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/
SOURCE: Emerging
Markets
Mindset Pharma (QB) (USOTC:MSSTF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mindset Pharma (QB) (USOTC:MSSTF)
Historical Stock Chart
From Aug 2023 to Aug 2024